EGFR and non-small cell lung carcinoma: Further in vivo assays such as non-small cell lung cancer patient-derived xenograft models which express high level of PDGFRβ, VEGFR2, EGFR, C-Kit will be carried out to demonstrate that whether R8 can be developed into a new member of MKI drug family.